Monograph Details
|
|
Nutrition
> Obesity
|
|
ADIPEX-P |
| Manufacturer |
|
Gate Pharmaceuticals |
| Legal Classification |
|
CIV |
| Pharmacological Class |
|
Sympathomimetic. |
| Generic Name |
|
Phentermine HCl 37.5mg; caps; scored tabs. |
| Indications |
|
Short-term monotherapy as adjunct in management of exogenous obesity in patients with initial body mass ≥30kg/m2, or ≥27kg/m2 in presence of other risk factors. |
| Children |
|
≤16 yrs: not recommended. |
| Adults |
|
≥16 yrs: 37.5mg once daily before or 1–2 hrs after breakfast, or 18.75mg 1–2 times daily. Avoid late evening dosing. |
| Contraindications |
|
Arteriosclerosis. Cardiovascular disease. Hypertension. Hyperthyroidism. Glaucoma. Agitation. Drug or alcohol abuse. During or within 14 days of MAOIs. |
| Precautions |
|
Discontinue if dyspnea, angina pectoris, syncope, lower extremity edema or other symptoms of primary pulmonary hypertension occur. Discontinue after a few weeks as tolerance to anorectic effect occurs. Diabetes. Prescribe limited supply to prevent overdose. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Hypertensive crisis with MAOIs. Concomitant SSRIs: not recommended. Avoid alcohol. Blocks guanethidine. Monitor antidiabetic agents. Possible risk of valvular heart disease with fenfluramine. |
| Adverse Reactions |
|
CNS overstimulation, dizziness, palpitations, arrhythmias, hypertension, psychosis, dry mouth, GI disturbances, urticaria, impotence, primary pulmonary hypertension, and/or regurgitant cardiac valvular disease. |
| How Supplied |
Caps—100
Tabs—100, 1000 |
|
|
|
|
